Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

European Society of Cardiology Conference In Brief

This article was originally published in The Gray Sheet

Executive Summary

Cypher DES: Johnson & Johnson/Cordis' Cypherdrug-eluting stent is significantly safer than bare-metal stents in complex cases where stents overlap, according to a meta-analysis of four Cypher trials presented by Martin Rothman, MD, London NHS Trust Hospital, at the European Society of Cardiology conference in Stockholm, Sept. 6. The analysis shows that overlapping Cypher stents are associated with a significantly lower rate of major adverse events than overlapping bare-metal stents - 7.4% versus 31.5% - and a lower rate of Q-wave myocardial infarction - 1.5% versus 4.6%. About 25% of all stent procedures require overlapping stents, according to Rothman. Studies included in the meta-analysis are SIRIUS, E-SIRIUS, DIRECT and SVELTE (1"The Gray Sheet" May 31, 2004, p. 13)...

You may also be interested in...



New labeling for Medtronic CRT

Revised labeling cleared by FDA for Medtronic's cardiac resynchronization therapy devices without defibrillation will reflect the technology's reduced risk of mortality and hospitalization. The labeling expansion is based upon results from the 813-patient CARE-HF trial of the firm's InSync and InSync III CRT-P devices, presented in 2005 (1"The Gray Sheet" Sept. 12, 2005, p. 13). The data, showing a 36%-40% reduction in all-cause mortality, provides validation that CRT devices "should be routinely used in patients with moderate to severe heart failure," William Abraham, MD, Ohio State University, says...

New labeling for Medtronic CRT

Revised labeling cleared by FDA for Medtronic's cardiac resynchronization therapy devices without defibrillation will reflect the technology's reduced risk of mortality and hospitalization. The labeling expansion is based upon results from the 813-patient CARE-HF trial of the firm's InSync and InSync III CRT-P devices, presented in 2005 (1"The Gray Sheet" Sept. 12, 2005, p. 13). The data, showing a 36%-40% reduction in all-cause mortality, provides validation that CRT devices "should be routinely used in patients with moderate to severe heart failure," William Abraham, MD, Ohio State University, says...

CRT-P Versus CRT-D: A Match-Up Likely Never To Be Seen – NEJM Editoral

Cardiac resynchronization with cardioverter defibrillation devices (CRT-D) will continue to be used more often than CRT-alone, even though the latter option may actually be better for some heart failure patients, according to John Jarcho, MD, Brigham & Women's Hospital, Boston

UsernamePublicRestriction

Register

OM016193

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel